AVEO Pharmaceuticals, Inc.
ANTI-NOTCH3 ANTIBODY

Last updated:

Abstract:

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.

Status:
Application
Type:

Utility

Filling date:

7 Oct 2021

Issue date:

28 Jul 2022